Lurasidon G.L. Pharma contains the active substance lurasidone and belongs to a group of medicines called antipsychotics. It is used to treat symptoms of schizophrenia in adults (aged 18 years and over) and adolescents aged 13-17 years.
Lurasidon G.L. Pharma works by blocking receptors in the brain to which the substances dopamine and serotonin attach. Dopamine and serotonin are neurotransmitters (substances that allow nerve cells to communicate with each other) that are involved in the symptoms of schizophrenia. By blocking their receptors, lurasidone helps to normalise the activity of the brain, reducing the symptoms of schizophrenia.
Schizophrenia is a disorder with symptoms such as hearing things, seeing or sensing things that are not there, mistaken beliefs, unusual suspiciousness, becoming withdrawn, incoherent speech and behaviour and emotional flatness. People with this disorder may also feel depressed, anxious, guilty, or tense.
This medicine is used to improve your symptoms of schizophrenia.
| Strength | Pack size |
| 18,5 mg | 10, 30 pcs. |
| 37 mg | 10, 30 pcs. |
| 74 mg | 10, 30 pcs. |
We ask for your understanding that due to the Austrian Medicines Act, certain further information is only accessible to medical professionals.
Login
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from hCaptcha to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Turnstile. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information